Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

N/AUnknownNCT03668522

Southern Medical University, China60 enrolled

Overview

H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Spinal Tumor

Interventions

Genetic testingOTHER

To determine whether H3F3AK27M exist in spinal glioma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation. Exclusion Criteria: * The tumor is recurrent or has been treated before operation.

Locations (1)

Nan fang hospital, Southern medical university

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

positive

positive of H3F3AK27M

Time frame: through study completion, an average of 1 year

Central Contacts

Lu Yuntao, M.D., Ph.D

CONTACT

13632101002 lllu2000@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.